



REC'D IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant(s): Yasmin Thanavala et al.

Serial No: 09/420,695

Filed: 10/19/1999

(1) Substitute Appeal Brief (in triplicate)
(1) Transmittal Form
(1) Fee Transmittal Form for FY 2001
(1) Postcard for acknowledgment.



Our Ref: RPP:156A US

Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	09/420,695
		Filing Date	October 19, 1999
		First Named Inventor	Yasmin Thanavala
		Group Art Unit	1651
		Examiner Name	M. Flood
Total Number of Pages in This Submission	11	Attorney Docket Number	PP:156A US

ENCLOSURES (check all that apply)


<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input checked="" type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) ** <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Extension of Time Request	**SUBSTITUTE Appeal Brief	
<input type="checkbox"/> Express Abandonment Request		
<input type="checkbox"/> Information Disclosure Statement		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Michael L. Dunn	
Signature		
Date	June 12, 01	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

Typed or printed name	Michael L. Dunn	Date	June 12, 01
Signature			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$)

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:

Deposit Account Number
04-1790Deposit Account Name

 Charge Any Additional Fee Required
Under 37 CFR 1.16, 1.17, 1.18 and 1.20 Applicant claims small entity status.
See 37 CFR 1.27

2. Payment Previously mailed April 2. 2001:

 Check Credit Card Money Order Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101	710	201 355 Utility filing fee	
106	320	206 160 Design filing fee	
107	490	207 245 Plant filing fee	
108	710	208 355 Reissue filing fee	
114	150	214 75 Provisional filing fee	
SUBTOTAL (1)			(\$)

2. EXTRA CLAIM FEES

	Extra Claims	Fee from below	Fee Paid
Total Claims			
Independent Claims			

Multiple Dependent

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103	18	203 9 Claims in excess of 20
102	80	202 40 Independent claims in excess of 3
104	270	204 135 Multiple dependent claim, if not paid
109	80	209 40 **Reissue independent claims over original patent
110	18	210 9 **Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		

**or number previously paid, if greater; For Reissues, see above

Complete if Known

Application Number	09/420,695
Filing Date	October 19, 1999
First Named Inventor	Yasmin Thanavala
Examiner Name	M. Flood
Group Art Unit	1651
Attorney Docket No.	PPR:156A US

FEE CALCULATION (continued)

3. ADDITIONAL FEES


Fee Code	Large Entity Fee (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105	130	205 65 Surcharge - late filing fee or oath		
127	50	227 25 Surcharge - late provisional filing fee or cover sheet		
139	130	139 130 Non-English specification		
147	2,520	147 2,520 For filing a request for ex parte reexamination		
112	920*	112 920* Requesting publication of SIR prior to Examiner action		
113	1,840*	113 1,840* Requesting publication of SIR after Examination action		
115	110	215 55 Extension for reply within first month		
116	390	216 195 Extension for reply within second month		
117	890	217 445 Extension for reply within third month		
118	1,390	218 695 Extension for reply within fourth month		
128	1,890	228 945 Extension for reply within fifth month		
119	310	219 155 Notice of Appeal		
120	310	220 155 Filing a brief in support of an appeal		
121	270	221 135 Request for oral hearing		
138	1,510	138 1,510 Petition to institute a public use proceeding		
140	110	240 55 Petition to revive - unavoidable		
141	1,240	241 620 Petition to revive - unintentional		
142	1,240	242 620 Utility issue fee (or reissue)		
143	440	243 220 Design issue fee		
144	600	244 300 Plant issue fee		
122	130	122 130 Petitions to the Commissioner		
123	50	123 50 Processing fee under 37 CFR 1.17(q)		
126	180	126 180 Submission of Information Disclosure Stmt		
581	40	581 40 Recording each patent assignment per property (times number of properties)		
146	710	246 355 Filing a submission after final rejection (37 CFR § 1.129(a))		
149	710	249 355 For each additional invention to be examined (37 CFR § 1.129(b))		
179	710	279 355 Request for Continued Examination (RCE)		
169	900	169 900 Request for expedited examination of a design application		
Other fee (specify)				

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Michael L. Dunn	Registration No. (Attorney/Agent)	25,330	Telephone	716-433-1661
Signature				Date	June 12, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RPP:156A US

**BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Yasmin Thanavala, et al. Art Unit: 1651
Serial No: 09/420,695
Filed: October 19, 1999
Examiner: M. Flood
For: ORAL IMMUNOLOGY
USING PLANT PRODUCT
CONTAINING HEPATITIS
SURFACE ANTIGEN

**SUBSTITUTE APPEAL BRIEF
(37 CFR 1.192)**

Box AF
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants respectfully appeal the decision of the Examiner finally rejecting Claims 1 and 4-18 set forth in the Office Action dated October 4, 2000. A Notice of Appeal was timely filed by the Applicants on February 5, 2001 (mailed to the U.S.P.T.O. on Feb. 2, 2001).

Real Parties in Interest

The real parties in interest are Health Research, Inc. and Boyce Thompson Institute For Plant Research, Inc., assignees of the entire interest in the patent application.

Related Appeals and Interferences

U.S. Patent Application Serial No. 09/464,416, filed 12/16/1999, claiming priority from the present application, is currently on appeal.

Status of Claims

The application originally contained 20 claims. Claims 2, 3, 19, and 20 have been cancelled. Claims 1, 4, 14 and 15 have been amended. Claims 1 and 4-18 are pending on Appeal.

Status of Amendments

Claims 1, 4, 14 and 15 have been amended. No amendments have been offered which have not been entered.

Summary of the Invention

The invention is a method for providing a serum IgM and IgG response to hepatitis B surface antigen (HBsAG), in an animal by feeding the animal with a substance comprising a physiologically acceptable plant material containing hepatitis B surface antigen in combination with an adjuvant. The combination causes serum IgM and IgG responses specific to HBsAg in excess of serum IgM and IgG responses specific to HBsAg caused by HBsAg alone.

The invention also includes the method as applied to humans and includes specific doses and procedures for that purpose.

Issues Presented for Review

Whether claims 1 and 4-18 are patentable under 35 USC 103 over U. S. Patent 5,935,570 to Arntzen et al. (B) in view of U.S. Patent 5,914,123 to Koprowski et al. (A), and further in view of Stites et al., Basic and Clinical Immunology, 7th ed., Appleton & Lange (U).

Grouping of Claims

The claims do not stand or fall together. It is not obvious from Claim 1 what methods, dosages and procedures would be suitable for obtaining a human immune response as set forth in subclaims.

Argument

The claims are unobvious to one skilled in the art and patentable over Arntzen et al. (B) in view of Koprowski et al. (A), and further in view of Stites et al. (U).

Arntzen et al. teaches a method for making a transgenic tobacco, tomato or potato that expresses HBsAg.

Notwithstanding the Examiner's assertion, Arntzen et al. does not teach "methods of making a transgenic plant expressing an immunogen derived from hepatitis B surface antigen, wherein the immunogen is capable of eliciting an immune response in an animal by consumption of the plant material."

Arntzen et al. pays lip service to raising an immune response by ingestion, but in fact give no examples or teachings for obtaining such a result. The only actual plant examples in Arntzen et al. relate to tomatoes and tobacco. There is no example of ingestion of either one and certainly no example showing that ingestion of either raises an immune response. In fact, ingestion of the transgenic tomato does not raise any significant immune response (see the enclosed Rule 132 Declaration of Dr. Yasmin Thanavala) and certainly tobacco cannot be used for such a purpose because it is toxic. Since there is no teaching in Arntzen et al. of how oral immunization to HBsAg might be accomplished using a transgenic plant, and in fact

the plants made in the examples do not function orally to raise an immune response, as Arntzen et al. alleges, it is clear that there is insufficient teaching or suggestion in Arntzen et al. to support a rejection of the present claims whether the reference is considered alone or in combination with the other cited references.

Simply making an unsupported allegation in a reference without a teaching as to how the allegation might be accomplished, is not a sufficient teaching to make a method for accomplishing the desired result obvious to one skilled in the art. Prophetic statements cannot be used to form the basis of a rejection, especially when they are unsupported and not true.

Arntzen et al. itself teaches and recognize that not all antigens would cause an immune response if ingested.

Arntzen et al. says in column 15 beginning at line 27,

“The vaccines are conventionally administered parenterally, by injection, for example either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, *in some cases*, oral formulations or aerosols.” (emphasis added).

But there is no teaching or suggestion in Arntzen et al. of how the “some cases” could be determined or how the “some cases” could be accomplished.

While Arntzen et al. suggest that tomato juice containing HBsAg might be used as a vaccine, in fact Arntzen provides no supporting data showing any immune response whatsoever to tomato juice or any other plant containing HBsAg. To the extent that Arntzen teaches that tomato juice or any other plant material containing HBsAg can be used as a vaccine, it is an inoperative reference since there is no teaching or suggestion as to how that might be done.

Simply ingesting the plant material, as suggested by Arntzen et al., does not confer immunity

at least in the sense that there is a protective response.

There is good reason for Arntzen's omission of data showing immune response to HBsAg by ingesting food material containing it, since prior to the present invention, in fact, there was little if any immune response whatsoever to HBsAg in orally ingested tomato juice or any other plant expressing HBsAg. See the Rule 132 Declaration of Dr. Thanavala of record. The response, if any, is clearly insufficient for that purpose.

Reference to the examples in the present specification clearly illustrates that priming of the subject of the immunization is required by either pre-vaccination or the use of an effective adjuvant. Arntzen et al. suggests neither. Arntzen et al. doesn't suggest an adjuvant for any purpose whatsoever and certainly does not suggest a combination with an adjuvant that permits the obtaining of a high immune response to orally administered HBsAg as required by the present claims.

Arntzen's suggestion of simple ingestion of plant material expressing HBsAg does not give a sufficient immune response to be considered protective. Arntzen discloses or suggests no way in which a high immune response could be orally obtained. *In any case there is certainly no suggestion of the enhanced immune response to HBsAg in orally administered plant material as provided by the method presently claimed.*

The Examiner states that Koprowski "teaches methods of making a transgenic plant containing a viral antigen which is fed to an animal or human to elicit an immune response." The Examiner's statement is inaccurate. **Koprowski at al. does not teach or suggest any**

method for making a transgenic plant but teaches a microorganism expressing a bioactive compound, e.g. an immunogenic rabies polypeptide. The microorganism may then be used to infect a plant as a parasite but does not alter the genetic character or expression of the plant.

Koprowski et al. suggest that their method has wide application, e.g. for treatment of viral infections, bacterial infections, fungal infections, protozoan infections, diabetes, immune disorders, cancer and heart disease. Koprowski et al. more specifically suggest that their method could be used for mucosal pathogens, e.g. rabies, respiratory syncytial virus, cholera, typhoid fever, herpes simplex types I and II, tuberculosis, pathogenic pneumococci, human immunodeficiency virus-1 (HIV-1) and human immunodeficiency virus-2 (HIV-2).

The only specific example given is for rabies. There is no enablement for the other suggested applications. If the disclosure actually enabled everything suggested, oral vaccines effective against Aids, cancer, and herpes, among many others, would be made available simply by following the teachings of the Koprowski et al patent. It is well known that this is not the case.

Koprowski et al. certainly does not enable or even reasonably suggest application for orally raising an immune response to hepatitis B surface antigen. The suggestion that an adjuvant be used is a gratuitous statement applied across the entire non-enabled spectrum of the Koprowski et al. disclosure. There is no suggestion of any specific adjuvant that would have such an effect for purposes of enablement and in fact there is no suggestion that any adjuvant would have any effect whatsoever upon oral immune response to hepatitis B surface antigen and

certainly not with a genetically modified plant because Koprowski suggests nothing concerning a genetically modified plant.

Stites et al. adds nothing to cure the inadequate teachings and suggestions of Arntzen et al. and Koprowski et al. Stites does not suggest anything whatsoever concerning hepatitis B and certainly suggests nothing suggesting that HBsAg would or could orally raise a highly effective immune response in the presence of a suitable adjuvant as presently claimed. Adjuvants "enhance" immune response. Arntzen does not teach any method showing any immune response to be enhanced and especially not with respect to HBsAg.

In view of the foregoing amendments and remarks, it is courteously requested that all rejections be withdrawn and all claims be allowed.

Conclusion

In view of the foregoing, it is clear that the pending claims are patentable over the cited prior art. Reversal of the Examiner and allowance of all claims are therefore respectfully requested.

Respectfully submitted,

Dated: June 12, 2001



Michael L. Dunn
Attorney for Applicant(s)
Reg. No. 25,330
P.O.Box 10
Newfane, New York 14108
Telephone: (716) 433-1661

Appendix

Reprinted below are the claims on appeal:

1. A method for providing a serum IgM and IgG response specific to hepatitis B surface antigen (HBsAG), in an animal by feeding the animal with a substance comprising a physiologically acceptable plant material containing hepatitis B surface antigen in combination with an adjuvant, said combination causing serum IgM and IgG responses specific to HBsAg in excess of serum IgM and IgG responses specific to HBsAg caused by HBsAg alone.
4. The method of claim 1 wherein the animal is a human.
5. The method of claim 4 wherein the plant material is from a plant that has been genetically altered to express said antigen.
6. The method of claim 5 wherein the human ingests sufficient plant material to provide from about 10 to about 100 micrograms of hepatitis B surface antigen per kilogram of body weight of the human.
7. The method of claim 6 wherein the human ingests sufficient plant material to provide from about 2 to about 5 grams of plant material per kilogram of body weight of the human.
8. The method of claim 5 wherein the human ingests said plant material a plurality of different times, said times being separated from each other by at least 5 days.
9. The method of claim 6 wherein the human ingests said plant material a plurality of different times, said times being separated from each other by at least 5 days.
10. The method of claim 7 wherein the human ingests said plant material a plurality of different times, said times being separated from each other by at least 5 days.

11. The method of claim 8 wherein the plurality of times is three times.
12. The method of claim 9 wherein the plurality of times is three times.

13. The method of claim 10 wherein the plurality of times is three times.
14. The method of claim 5 wherein the plant material is a material from a plant of the family *Solanaceae*.
15. The method of claim 6 wherein the plant material is a material from a plant of the family *Solanaceae*.
16. The method of claim 14 wherein the plant is a potato.
17. The method of claim 15 wherein the plant is a potato.
18. The method of claim 14 wherein the plant is a tomato.